Aptose-Hanmi deal closing delayed to June pending Korean regulatory approvals
Aptose Biosciences announced that closing of its previously announced Plan of Arrangement with Hanmi Pharmaceutical has been further delayed due to pending Korean regulatory approvals, now targeted for June. The company received an additional US$2.0 million advance from Hanmi und
View filing at SEC.gov →